- 20+ years in FDA policy development and legislative matters
- Specialist in formulating strategic solutions to challenging regulatory matters
- Former Food and Drug Administration (FDA) Chief of Staff
- Previous experience in federal health care policy and U.S. regulatory issues, as well as FDA policy development and strategic planning
With more than 20 years of leadership experience at the Food and Drug Administration (FDA), on Capitol Hill, and at a leading global pharmaceutical company, Patrick Ronan brings a comprehensive understanding of the health care sector to Greenleaf.
Prior to founding Greenleaf, Patrick served as Vice President of Regulatory Policy & External Affairs at Novartis Pharmaceuticals Corporation, where he supervised U.S. regulatory policy issues and advised all brand teams on FDA-related regulatory matters. In addition, Patrick supervised state regulatory and coverage policy and advocacy activities. At Novartis, Patrick formulated and implemented a regulatory policy agenda, working on policy matters and providing strategic direction to brand teams on their interactions with the FDA on a full range of pre- and postmarket product-specific issues.
Prior to joining Novartis, Patrick served as FDA’s Chief of Staff from 2005–2007 and in other leadership roles at the agency preceding this role. As Chief of Staff, Patrick was the principal advisor on all agency issues to former Commissioners Dr. Andrew von Eschenbach and Dr. Lester M. Crawford. Patrick’s FDA career began with his appointment as Assistant Commissioner of Legislation by then Commissioner Dr. Mark McClellan. The following year, Patrick was elevated to Associate Commissioner of Legislation and then Chief of Staff. His work with Congress contributed to the enactment of important modernizations of public health laws governing the regulation of drugs, biologics, medical devices, and foods.
Patrick’s interactions with Congress as FDA Chief of Staff were a natural extension of his prior experience on Capitol Hill, where he served as Majority Counsel to the Committee on Energy and Commerce for then Chairman W.J. “Billy” Tauzin and Chairman Joe Barton from 2002–2004. In this capacity on the Committee, Patrick became one of the lead drafters of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) and authored numerous pieces of food- and drug-related legislation that were signed into law. Earlier, Patrick served the Washington, D.C.-based Biotechnology Industry Organization (BIO) as Director of Government Relations and worked for several Members of Congress who represented the constituents of Nevada and Pennsylvania.
Patrick received his B.A. from the University of Nevada, Reno; his J.D. from the Georgetown University Law Center in Washington, D.C.; and his Masters in Business Administration from the University of Pennsylvania’s Wharton School.